share_log

Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5

Benzinga ·  Jul 17, 2023 10:25

Alliance Global Partners analyst James Molloy initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $7.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment